Paris-based LimFlow’s results came from its Promise II U.S. pivotal trial. They were published in today’s issue of the New England Journal of Medicine (NEJM). Data demonstrated 66% amputation-free survival at six months with the LimFlow system.
Study backs LimFlow system for treating chronic limb-threatening ischemia
LimFlow announced that new study results demonstrated statistically significant survival with its chronic limb-threatening ischemia (CLTI) treatment.